Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Med Acupunct ; 35(6): 334-341, 2023 Dec 01.
Article in English | MEDLINE | ID: mdl-38162551

ABSTRACT

Objective: This study investigated the effect of letrozole with/without meridian-infusion percutaneous electrical stimulation on the rates of ovulation-induced pregnancy in patients with obese polycystic ovary syndrome (obPCOS). Materials and Methods: Patients with obPCOS, ages 20-40, each with a body mass index (BMI) ≥24 kg/m2, and/or waist circumference ≥80 cm, and at least 1 side tubal patency were enrolled at the Guangdong Women and Children Hospital, Guangzhou, China. They were divided into 2 groups: ZLT [Ziwu Liuzhu + transcutaneous electrical acupoint stimulation] and control. Baseline conditions and pregnancy status were collected for all patients. Multivariate Cox regression analysis and sensitivity analysis of propensity score matching (PSM) were performed for the groups after multiple interpolations. Results: From July 2021 to September 2022, 345 patients with obPCOS were recruited: 53 cases/69 cycles in the ZLT group and 292 cases/396 cycles in the control group. The 2 sets of baselines were flush. The anovulatory cycle rates were: ZLT, 2.89% (2/69); and control, 1.77% (7/396); P > 0.05. Multifollicle growth-cycle rates were: ZLT, 0% (0/69); and control, 0.76% (3/396); P > 0.05. Multivariate COX regression analysis showed adjusted hazard ratio (aHR) 95% confidence interval (CI): 2.11 (1.19, 3.73); P = 0.011. Multivariate Cox regression analysis with multiple imputation showed aHR 95% CI: 2.11 (1.19, 3.73); P = 0.013. In the overweight group (24-28 kg/m2), the pregnancy rate of the control and ZLT groups were 20.2% and 32.3%, respectively, aHR 95% CI: 1.76 (0.87,3.55); P = 0.113. In the obese cohort (≥ 28 kg/m2), the control and ZLT groups, pregnancy rates were 10.7% and 27.3%, respectively, aHR 95% CI: 3.46 (1.21, 9.92); P = 0.021; (Pfor interaction = 0.369). The caliper value was set as 0.2 for BMI and antral-follicle count, and PSM was performed at 1:1, aHR 95%CI: 2.45 (1.01, 5.96); P = 0.048. Conclusions: Letrazole + ZLT had a positive effect on ovulation-induced pregnancy rates in patients with obPCOS.

2.
Medicine (Baltimore) ; 99(15): e19680, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32282721

ABSTRACT

BACKGROUND: Knee osteoarthritis (KOA) is one of the most common chronic muscular diseases in old people. The purpose of this meta-analysis was to compare celecoxib and diclofenac sodium in patients with knee osteoarthritis (KOA). METHODS: Randomized controlled trials (RCTs) and clinical controlled trials (CCTs) comparing the use of celecoxib and diclofenac sodium in KOA patients were retrieved from each database from the date of database inception to September 2019. The outcome measurements were the treatment effect, visual analog scale (VAS) score, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and complication rate. The pooled data were evaluated with Review Manager 5.3.5. RESULTS: The literature will provide a high-quality analysis of the current evidence supporting celecoxib for KOA based on various comprehensive assessments including the treatment effect, visual analog scale (VAS) score, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) level, and complication rate. CONCLUSION: This proposed systematic review will provide up-to-date evidence to assess the effect of celecoxib in the treatment for patients with KOA. RESEARCH REGISTRY REGISTRATION NUMBER:: reviewregistry827.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal , Celecoxib , Diclofenac , Osteoarthritis, Knee , Female , Humans , Male , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Blood Sedimentation/drug effects , C-Reactive Protein/drug effects , Celecoxib/therapeutic use , Diclofenac/therapeutic use , Osteoarthritis, Knee/complications , Osteoarthritis, Knee/drug therapy , Osteoarthritis, Knee/epidemiology , Quality Assurance, Health Care , Randomized Controlled Trials as Topic , Treatment Outcome , Visual Analog Scale , Meta-Analysis as Topic , Systematic Reviews as Topic
3.
Medicine (Baltimore) ; 99(9): e19370, 2020 Feb.
Article in English | MEDLINE | ID: mdl-32118781

ABSTRACT

BACKGROUND: Knee osteoarthritis (KOA) is one of the most common chronic muscular diseases in old people. In recent years, people are more and more interested in the use of Chinese herbal medicine (CHM) in the treatment of KOA, such as kidney-tonifying and blood-activating medicinal herbs (KTBAMs) in the treatment of KOA. Many studies have confirmed that KTBAMs are effective in the treatment of KOA. However, it is still unknown whether KTBAMs and NSAIDs are more effective in the treatment of KOA. Therefore, we evaluated the efficacy and safety of KTBAMs and NSAIDs in the treatment of KOA. METHODS: Randomized controlled trials (RCTs) from online databases including PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, Chinese Scientific Journal Database, Wanfang Data, and Chinese Biomedical Literature Database that compared the efficacy of KTBAMs and NSAIDs in the treatment of KOA were retrieved. The main outcomes included the evaluation of functional outcomes, pain and adverse effects. The Cochrane risk of bias (ROB) tool was used to assess methodological quality. RESULTS: The literature will provide a high-quality analysis of the current evidence supporting KTBAMs for KOA based on various comprehensive assessments including the total effective rate, visual analog scale scores, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Lequence scores, Knee Society Scale (KSS) scores, and adverse effects. CONCLUSION: This proposed systematic review will provide up-to-date evidence to assess the effect of KTBAMs in the treatment for patients with KOA. RESEARCH REGISTRY REGISTRATION NUMBER: : reviewregistry 783.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/standards , Osteoarthritis, Knee/drug therapy , Plants, Medicinal/metabolism , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Clinical Protocols , Humans , Kidney/drug effects , Osteoarthritis, Knee/physiopathology
4.
Medicine (Baltimore) ; 99(4): e18910, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31977905

ABSTRACT

BACKGROUND: Knee osteoarthritis (KOA) is a common disease in the elderly, which seriously reduces the quality of life of patients and increases the social burden. proximal fibula osteotomy (PFO) and high tibial osteotomy (HTO) are effective methods to treat KOA. However, it is not entirely clear which method has the advantage. Therefore, we evaluated the efficacy and safety of HTO and PFO in the treatment of KOA. METHODS: Randomized controlled trials from online databases including PubMed, Embase, the Cochrane Library, China National Knowledge Infrastructure, Chinese Scientific Journal Database, Wanfang Data and Chinese Biomedical Literature Database that compared the efficacy of HTO and PFO in the treatment of KOA were retrieved. The main outcomes included hospital for special surgery (HSS) knee scores, knee society knee scoring system (KSS) score, visual analog scale (VAS) knee pain scores, western ontario and McMaster universities osteoarthritis index score, operation time, intraoperative bleeding volume, hospitalization time, complications. The Cochrane risk of bias tool was used to assess methodological quality. RESULTS: The literature will provide a high-quality analysis of the current evidence supporting HTO for KOA based on various comprehensive assessments including HSS scores, KSS score, VAS scores, western Ontario and McMaster universities osteoarthritis index score, operation time, intraoperative bleeding volume, hospitalization time, and complications. CONCLUSION: This proposed systematic review will provide up-to-date evidence to assess the effect of HTO in the treatment for patients with KOA.


Subject(s)
Osteoarthritis, Knee/surgery , Osteotomy/methods , Fibula/surgery , Humans , Meta-Analysis as Topic , Randomized Controlled Trials as Topic , Systematic Reviews as Topic , Tibia/surgery
5.
Front Pharmacol ; 10: 882, 2019.
Article in English | MEDLINE | ID: mdl-31447677

ABSTRACT

Background: Several epidemiological articles have reported the correlations between anti-osteoporosis medication and the risks of fractures in male and female subjects, but the specific efficacy of anti-osteoporosis medication for male subjects remains largely unexplored. Objective: The aim of this study was to evaluate the correlation between anti-osteoporosis medication and the risk of fracture in relation to low bone mass [including outcomes of osteoporosis, fracture, and bone mineral density (BMD) loss] in male subjects analyzed in studies within the updated literature. Methods: Randomized controlled trials (RCTs) that analyzed the effectiveness of a treating prescription for male subjects with osteoporosis (or low BMD) and that focused on the outcomes of fracture were included. Relevant studies from Embase, Web of Science, PubMed, and Chinese database of CNKI were retrieved from inception to January 30th, 2019. Two staff members carried out the eligibility assessment and data extraction. The discrepancies were settled by consultation with another researcher. We calculated the pooled relative risks (RRs) based on 95% confidence intervals (CIs). Results: Twenty-seven documents (28 studies) with 5,678 subjects were identified. For the category of bisphosphonates, significant results were observed in pooled analyses for decreased risk of the vertebral fracture domain (RR, 0.44 [95% CI, 0.31-0.62]), nonvertebral fracture domain (RR, 0.63 [95% CI, 0.46-0.87]), and clinical fracture domain (RR, 0.59 [95% CI, 0.48-0.72]) compared with those of controls. Participants with bisphosphonates had a 56% (95% CI = 38-69%) lower risk of vertebral fractures, 37% (95% CI = 13-54%) lower risk of nonvertebral fractures, and 41% (95% CI = 28-52%) lower risk of clinical fractures. Furthermore, meta-analyses also demonstrated a decreased risk of the vertebral fracture domain via treatment with risedronate (RR, 0.45 [95% CI, 0.28-0.72]) and alendronate (RR, 0.41 [95% CI, 0.23-0.74]), but not with calcitriol, calcitonin, denosumab, ibandronate, monofluorophosphate, strontium ranelate, teriparatide, or zoledronic acid, compared with that of controls. Conclusions: This systematic review confirms that bisphosphonates were connected with a decreased risk of vertebral fractures, nonvertebral fractures, and clinical fractures for male subjects with osteoporosis. Future research is needed to further elucidate the role of nonbisphosphonates in treating fractures of osteoporosis subjects.

6.
Trials ; 20(1): 520, 2019 Aug 20.
Article in English | MEDLINE | ID: mdl-31429810

ABSTRACT

BACKGROUND: Coronary artery disease (CAD) is one of the most common types of the cardiovascular disease. Previous pilot trials have suggested that Traditional Chinese Medicine (TCM) has brought clinical benefits for patients with CAD. We will conduct this trial to determine the efficacy and safety of Shenzhu Guanxin Recipe Granules (SGR) for the treatment of patients with CAD. METHODS: This randomized controlled trial recruited 190 patients who were diagnosed with CAD by clinical manifestation and examination and in which coronary computed tomography angiography (CCTA) showed 50-70% stenosis, with soft or mixed plaque types. The included participants were randomly assigned to the case group and control group using a 1:1 allocation ratio; patients in the case group received SGR and usual care, and those in the control group received placebo (6 g/day for 6 months) and usual care. The endpoint of the study included Calcium Coverage Score (CCS), C-reactive protein (CRP) level, and the levels of blood lipids, tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), interleukin-6 (IL-6), and ATP-binding membrane cassette transporter A1 (ABCA1) were calculated before recruiting and at the sixth month. The indicators were Seattle Angina Questionnaire (SAQ) and TCM Syndrome Questionnaire scores at 0, 3, and 6 months. DISCUSSION: This clinical trial may provide reliable evidence regarding the clinical effectiveness and safety of SGR therapy for patients with CAD diagnosed by clinical manifestation and examination, in which CCTA showed 50-70% stenosis, with soft or mixed plaque types. TRIAL REGISTRATION: ClinicalTrials.gov, ID: ChiCTR1900020501 . The trial was registered on 25 December 2018.


Subject(s)
Cardiovascular Agents/therapeutic use , Coronary Artery Disease/drug therapy , Coronary Stenosis/drug therapy , Drugs, Chinese Herbal/therapeutic use , Adolescent , Adult , Aged , Cardiovascular Agents/adverse effects , China , Coronary Artery Disease/diagnostic imaging , Coronary Stenosis/diagnostic imaging , Double-Blind Method , Drugs, Chinese Herbal/adverse effects , Female , Humans , Male , Middle Aged , Multicenter Studies as Topic , Plaque, Atherosclerotic , Randomized Controlled Trials as Topic , Severity of Illness Index , Time Factors , Treatment Outcome , Young Adult
7.
Medicine (Baltimore) ; 98(12): e14872, 2019 Mar.
Article in English | MEDLINE | ID: mdl-30896633

ABSTRACT

BACKGROUND: Stroke is one of the leading causes of death and disability for adult men and women worldwide, and a number of studies have explored the influences of smoking on stroke. However, few studies have discussed the relationship between stroke and smoking with consideration of the following factors: sex, the number of cigarettes smoked per day, stroke subtype, and the follow-up duration. Consequently, we aimed to extend previous work by using a systematic review to explore the relationship between stroke and cigarette smoking in reference to the above factors. METHODS: A systematic review was conducted using the PubMed, Embase, and Cochrane Central Register databases and the following search criteria: ["stroke" (MeSH) and "smoking" (MeSH)]. All analyses were conducted with Stata, and funnel plots and Egger regression asymmetry tests were used to assess publication bias. RESULTS: The meta-analysis included 14 studies involving 303134 subjects. According to the meta-analysis, smokers had an overall increased risk of stroke compared with nonsmokers, with a pooled odds ratio (OR) of 1.61 (95% confidence interval [CI]: 1.34-1.93, P < .001). A subgroup analysis conducted based on smoking status revealed ORs of 1.92 (95% CI: 1.49-2.48) for current smokers and 1.30 (95% CI: 0.93-1.81) for former smokers. In addition, the relationship between stroke of any type and smoking status was also statistically significant; current smokers had an increased risk of stoke compared with nonsmokers (OR: 1.46, 95% CI: 1.04-2.07, P < .001), which was influenced by sex (men: OR: 1.54, 95% CI: 1.11-2.13, P = .002; women: OR: 1.88, 95% CI: 1.45-2.44, P < .023). From the analysis, we also observed that passive smoking increased the overall risk of stroke by 45% (OR: 1.45, 95% CI: 1.0-2.11, P < .05). Based on the dose-response meta-analysis, the risk of stroke increased by 12% for each increment of 5 cigarettes per day.


Subject(s)
Smoking/epidemiology , Stroke/epidemiology , Dose-Response Relationship, Drug , Humans , Odds Ratio , Risk Assessment , Risk Factors , Sex Factors , Smokers/statistics & numerical data , Stroke/classification , Tobacco Smoke Pollution/statistics & numerical data
8.
Medicine (Baltimore) ; 98(3): e14049, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30653112

ABSTRACT

BACKGROUND: Several studies have reported the benefits of traditional Chinese exercises (TCEs) on hypertension; however, a consensus regarding the effectiveness and safety of TCEs for patients with hypertension has not been reached. METHODS AND RESULTS: Only randomized controlled trials were included in our study. A total of 16 articles involving 1164 patients with hypertension met the inclusion criteria. The results showed that TCEs can reduce BP, blood lipids (including total cholesterol and triglyceride levels) and endothelin levels and improves quality of life in hypertensive patients, however, the low-quality of the included studies made the results be of questionable significance. CONCLUSIONS: The results of this review suggest that there is no firm evidence to support the objective effectiveness and safety of TCEs for hypertension because of the poor quality of the studies. Well-designed, randomized placebo-controlled trial with objective outcome measures should be conducted in the future.


Subject(s)
Exercise Therapy/methods , Hypertension/therapy , Medicine, Chinese Traditional/methods , Adult , Aged , Female , Humans , Male , Middle Aged , Randomized Controlled Trials as Topic , Treatment Outcome
9.
Medicine (Baltimore) ; 97(39): e12489, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30278538

ABSTRACT

BACKGROUND: Several epidemiological studies had been carried out in different population cohorts to estimate the relationship between the shortened telomere length and stroke. However, the results still remained dispute. Consequently, we conducted this meta-analysis to estimate the relationship between them. METHODS: PubMed, EMBASE, and Web of Science were systematically searched for related articles to evaluate the association between "stroke" and "telomere length. STATA 12.0 software was used to perform the meta-analysis. The Cochran Q test and inconsistency index (I) were used to assess the heterogeneity. Begg funnel plot and Egger test were used to assess publication bias. RESULTS: The meta-analysis was composed of 11 studies, consisting of 25,340 participants. We found a significant relationship between shortened telomere length and stroke (OR: 1.50, 95% CI: 1.13-2.0; P = .005); however, in the prospective and retrospective study subgroup, we did not find a statistical significant relationship between shortened telomere length and stroke (the prospective subgroup: OR: 1.41, 95% CI: 1-1.98; P = .051) (the retrospective subgroup: OR: 1.89, 95% CI: 0.96-3.72; P = .067).


Subject(s)
Genetic Predisposition to Disease/genetics , Stroke/genetics , Telomere/genetics , Aged , Aged, 80 and over , Female , Genetic Predisposition to Disease/epidemiology , Humans , Male , Middle Aged , Prospective Studies , Publication Bias , Retrospective Studies , Risk Factors , Stroke/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...